What did @raya.arya actually say?
She described starting peptide therapy and experiencing a brutal week of GI symptoms: bloating, acid burping, liquid diarrhea, and pain severe enough to wake her at night. She warned viewers to "be careful" after injecting into her abdomen while already dealing with menstrual bloating and pre-existing gastric issues. She also mentioned feeling an immediate sensation at the injection site, saying she "felt this like, you're feeling" after pinning into her stomach. The framing is personal experience, not a clinical claim, which matters for how we evaluate it.
She's not selling anything here. She's describing a bad experience and telling people to watch out. That's actually a reasonable thing to do. The question is whether her experience reflects known pharmacology or whether something else was going on.
Does the science back this up?
Yes, and no. GI side effects from peptides are real and documented, but the mechanism depends heavily on which peptide she was using. BPC-157, one of the most commonly self-administered peptides, has shown gastroprotective effects in animal studies, not gastro-destructive ones. GHRPs like ipamorelin and CJC-1295 can stimulate gastric motility and acid secretion, which would better explain her symptoms.
A 2018 review by Chang et al. in Current Pharmaceutical Design documented that growth hormone secretagogues increase ghrelin receptor activity, which can accelerate gastric emptying and stimulate hydrochloric acid output. That tracks with "burping acidity." The liquid diarrhea is harder to pin on any specific peptide without knowing what she was using. Injection site irritation from subcutaneous abdominal injections is also well-established, particularly when injecting into already-inflamed or bloated tissue. Menstrual-related GI hypersensitivity is a real phenomenon documented in irritable bowel research (Heitkemper and Chang, 2009, Gastroenterology Clinics of North America), which likely worsened her baseline sensitivity that week.
What did they get wrong (or right)?
She got the general warning right: starting peptides with pre-existing GI issues is genuinely risky, and timing matters. Injecting into an already-distended, sensitive abdomen during menstruation, when visceral pain thresholds are lower, is a reasonable thing to flag. Credit where it's due.
What she got wrong, or at least left dangerously vague, is not naming which peptide caused this. Lumping all peptides together as a GI hazard is misleading. BPC-157 is actually being studied as a potential GI healer in animal models, not a trigger for diarrhea and acid reflux. If she was using a GHRP or MK-677 (technically a small molecule, not a peptide, but often grouped with them), those have documented nausea and GI motility effects. MK-677 in particular is associated with increased appetite and GI discomfort, especially in the first few weeks. Without specifics, viewers can't actually apply her warning usefully.
The "felt this like, you're feeling" injection sensation is harder to evaluate. Subcutaneous injections into the periumbilical area can cause referred sensations. That's plausible. It's not a pharmacological effect from the peptide itself hitting the stomach.
What should you actually know?
GI side effects from peptide therapy are real but not universal, and the peptide in question matters enormously. Growth hormone secretagogues can accelerate gastric motility and raise acid output. Combining any new injectable with a period of existing GI stress is poor timing. If you have a history of gastric issues, acid reflux, or IBS, starting peptides during a flare is going to make attribution almost impossible and may genuinely worsen symptoms.
A few things worth knowing:
- MK-677 causes GI side effects in a meaningful percentage of users, particularly nausea and increased hunger signals that can feel like stomach pain.
- Subcutaneous injection into abdominal fat is generally safe but injecting into an already-distended or inflamed area adds unnecessary discomfort and may affect absorption.
- Menstrual-phase GI hypersensitivity is real. Estrogen and progesterone fluctuations affect gut motility and visceral pain perception (Heitkemper and Chang, 2009).
- None of this is a reason to avoid peptides categorically. It is a reason to start low, start during a stable baseline, and not inject into symptomatic tissue.
If you're considering peptide therapy, the right approach is a supervised protocol with someone who can assess your GI history before you start, not a TikTok trial-and-error experiment.